These results indicate that EPHA10 represents a promising target in terms of both targeted therapy and immunotherapy, given that monoclonal antibodies not only specifically bind and interact with the membrane-bound EPHA10, but also initiate anticancer immune responses by marking EPHA10-expressing BC cells and helping the immune system recognize and destroy them. This evidence concerns the gene EPHA10 and breast cancer.